定量CT在肿瘤恶液质定量诊断及疗效评估中的研究进展

doi:10.16689/j.cnki.cn11-9349/r.2020.04.023

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (432 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要肿瘤患者在治疗过程中身体组分的变化受多种因素影响，并与患者的预后不良密切相关。晚期恶性肿瘤患者常伴有恶液质，其发病机理尚未阐明，严重影响了患者的生活质量及预后。肿瘤恶液质患者身体组分的变化常对临床有一定提示和预警意义，既往通过体质指数对恶液质进行评估，忽略了肌肉脂肪含量的变化及异常脂肪浸润，无法准确对身体组分进行定量分析。定量CT（QCT）能够全面、准确、高效的定量测定患者身体组分的信息，包括肌肉密度、骨密度（BMD）以及体部脂肪含量等，这些参数可作为评估患者营养状态参考指标，在评估肿瘤恶液质具有较大优势。本文就近年来国内外学者对QCT在恶性肿瘤恶液质定量诊断及QCT基于身体组分变化进行肿瘤治疗后的疗效评估的应用进展进行综述，旨在提高QCT在肿瘤恶液质诊断与疗效评估中的应用价值。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陈东
	王传彬
	史彬
	高飞
	董江宁

关键词 ：定量CT, 恶性肿瘤, 恶液质, 诊断, 疗效评估

Abstract：The changes in body composition of cancer patients during treatment are affected by many factors and are closely related to the poor prognosis of patients. Patients with advanced malignant tumors are often accompanied by cachexia, which seriously affects the patients quality of life and prognosis. The pathogenesis of cancer cachexia has not been elucidated. Changes in the body composition of patients with early cancer cachexia often have certain hints and early warning significance for the clinicians. In the past, the BMI was used to assess cachexia, ignoring changes in muscle fat content and abnormal fat infiltration, and it was impossible to accurately quantify body components. Quantitative computed tomography (QCT) can comprehensively, accurately and efficiently quantify the patients muscle density, bone mineral density (BMD) and body fat content, etc. which can be used as relevant indicators for evaluating the patients nutritional status, and those relevant information has great advantages in evaluating cancer cachexia. The author summarizes quantitative diagnosis of cachexia and the application progress of QCT in evaluating the efficacy of cancer treatment based on changes in body composition are reviewed, aiming to improve the application value of QCT in the diagnosis and efficacy evaluation of cancer cachexia.

Key words： Quantitative computed tomography Malignant tumor Cachexia Diagnosis Therapeutic effect evaluation

基金资助:安徽省肿瘤医院青年基金项目（2020YJQN010）

通讯作者: 董江宁，电子邮箱：dongjn@163.com

引用本文:

陈东，王传彬，史彬，高飞，董江宁. 定量CT在肿瘤恶液质定量诊断及疗效评估中的研究进展[J]. 肿瘤代谢与营养电子杂志, 2020, 7(4): 497-501.
Chen Dong, Wang Chuanbin, Shi Bin, Gao Fei, Dong Jiangning. Research progress of QCT in quantitative diagnosis of cancer cachexia syndrome and evaluation of curative effect. Electron J Metab Nutr Cancer, 2020, 7(4): 497-501.

1.CAAN B J, CESPEDES FELICIANO E M, CANDYCE H, et al. The importance of body composition in explaining the overweight paradox in cancer-counterpoint［J］. Cancer res, 2018, 78(8): 1906-1912.
2.EBADI M, MARTIN L, GHOSH S, et al. Subcutaneous adiposity is an independent predictor of mortality in cancer patients ［J］. Br J Cancer, 2017, 117(1): 148-155.
3.KENNETH F, FLORIAN S, STEFAN D A, et al. Definition and classification of cancer cachexia: an international consensus ［J］. Lancet Oncol, 2011, 12(5):489-495.
4.李凯, 陈捷, 赵林芬, 等. 中国人群定量CT(QCT)脊柱骨密度正常参考值的建立和骨质疏松症QCT诊断标准的验证［J］. 中国骨质疏松杂志, 2019, 25(9): 1257-1262, 1272.
5.CANN C E, GENANT H K. Precise measurement of vertebral mineral content using computed tomography ［J］. J Comput Assist Tomogr, 1980, 4(4):493-500.
6.ZHANG X, HUA T, ZHU J, et al. Body compositions differently contribute to BMD in different age and gender: A pilot study by QCT ［J］. Arch Osteoporos, 2019, 14(1): 31.
7.STEWART G D, SKIPWORTH R J E, FEARON K C H. Cancer cachexia and fatigue ［J］. Clin Med(Lond), 2006, 6(2): 140-143.
8.FEARON K, STRASSER F, ANKER S D, et al. Definition and classification of cancer cachexia: an international consensus ［J］. Lancet Oncol, 2011, 12(5):489-495
9.MOURTZAKISM M, PRADO C M M, LIEFFERS J R. et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care.［J］.Appl Physiol Nutr Metab.2008, 33(5):997-1006.
10.ROLLINS K E, JAVANMARD-EMAMGHISSI H, AWWAD A, et al. Body composition measurement using computed tomography: does the phase of the scan matter?［J］.Nutrition, 2017, 41:37-44.
11.TAN B H L, BIRDSELL L A, MARTIN L, et al.Sarcopenia in overweight or obese patient is an adverse prognostic factor in pancreatic cancer［J］. Clin Cancer Res, 2009, 15(22):6973-6979.
12.中华医学会放射学分会骨关节学组, 中国医师协会放射医师分会肌骨学组, 中华医学会骨科学分会骨质疏松学组, 等. 骨质疏松的影像学与骨密度诊断专家共识［J］. 中华放射学杂志, 2020, 54(8): 745-752.
13.万颖, 邹德环, 朱旭生, 等. 不同治疗方法对绝经后乳腺癌患者骨密度的影响［J］. 中华生物医学工程杂志, 2009, 15(2): 112-114.
14.XU X M, LI N, LI K, et al. Discordance in diagnosis of osteoporosis by quantitative computed tomography and dual-energy X-ray absorptiometry in Chinese elderly men ［J］. J Orthop Translat, 2019, 18: 59-64
15.HOPSON M B, ONISHI M, AWAD D, et al. Prospective study evaluating changes in bone quality in premenopausal women with breast cancer undergoing adjuvant chemotherapy ［J］. Clinical breast cancer, 2020, 20(3).
16.徐黎, 端木羊羊, 张勇, 等. 定量CT测量动物肝脏脂肪含量的试验研究［J］. 放射学实践, 2017, 32(5): 466-470.
17.王玲, 汪伟, 邓微, 等. 定量CT测量腹部脂肪面积及分布的重复性研究［J］. 中国骨质疏松杂志, 2012, 18(11): 999-1003.
18.奚秋磊, 谈善军, 张树泽, 等. 少肌症可预测消化道癌腹部手术患者不良预后:一项前瞻性队列研究［J］.中国临床医学, 2019, 26(5): 679-685.
19.LEE J, LIN J B, WU M H, et al.Muscle radiodensity loss during cancer therapy is predictive for poor survival in advanced endometrial cancer［J］. J Cachexia Sarcopenia Muscle, 2019, 10(4):814-826.
20.REISINGER K W, BOSMANS JWAM, UITTENBOGAART M, et al. Loss of skeletal muscle mass during neoadjuvant chemoradiotherapy predicts postoperative mortality in esophageal cancer surgery［J］. Ann Surg Oncol, 2015, 22(13): 4445-4452.
21.NAKAMURA N, HARA T, SHIBATA Y, et al.Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma［J］. Ann Hematol,2015,94(12):2043-2053.
22. ISHIHARA H, KONDO T, OMAE K, et al. Sarcopenia predicts survival outcomes among patients with urothelial carcinoma of the upper urinary tract undergoing radical nephroureterectomy: a retrospective multi-institution study ［J］. Int J Clin Oncol, 2017, 22(1):1364-144.
23.KASTE S C, JONES-WALLACE D, ROSE S R, et al. Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their development ［J］. Leukemia, 2001, 15(5): 728-734.
24.MUESKE N M, MITTELMAN S D, WREN T A L, et al. Myosteatosis in adolescents and young adults treated for acute lymphoblastic leukemia ［J］. Leuk Lymphoma, 2019, 60(13): 3146-3153.
25.王克扬, 梁宇霆, 李彪, 等. 妇科恶性肿瘤和良性病变的腹盆部脂肪组织分布研究［J］. 重庆医学, 2016, 45(30): 4186-4189.
26.BARACOS V E. Skeletal muscle anabolism in patients with advanced cancer［J］. Lancet Oncol, 2015, 16(1):13-14.
27.魏君, 贾瑞娟, 邱磊, 等. 定量CT测量的腹部脂肪分布在腹腔镜直肠癌全手术指导中的临床意义［J］. 河北医学, 2020, 26(1): 114-118.
28.黎鑫, 周业江. 内脏脂肪面积对腹腔镜结直肠癌根治术患者预后的影响［J］. 医学研究生学报, 2019, 32(11): 1193-1197.
29.崔久嵬, 刘雪莲, 李薇.人体成分分析在抗肿瘤药物药动学及毒性预测中的研究进展［J/CD］.肿瘤代谢与营养电子杂志, 2018, 5(1):19-25.
30.WANG Z M, GAO S, SUN C X, et al. Clinical significance of serum adiponectin and visfatin levels in endometrial cancer［J］. Int J Gynaecol Obstet, 2019, 145(1): 34-39.